	response of Levetiracetam should be NLT 0.995	
LOD/LOQ	The% of RSD for area response of Levetiracetam from six replicates at LOQ level should be NMT 10.0%	LOD/LOQ parameters meets the requirements of method validation.
Method Precision	% of RSD for purity and Area at 100% of specification and 150% of specification levet not more than 2.0%	Method precision parameter meets the criteria and %RSD value of retention times, peak areas were found to be less than 2%.
Range	At 25% to 150% of specification level to be precise , accurate and linear.	Meet the criteria At 25% to 150% of specification level and found it to be precise , accurate and linear.
Ruggedness (or) Intermediate Precision:	Different system , by different analyst and in different column the %RSD for area & purity at 100% of specification level was not more than 2.0%.	%RSD for area & purity at 100% of specification level was calculated which is well within the acceptance criteria of not more than 2.0%
Test solution and Mobile phase Stability	Established the stability of standard solution ,test solution and mobile phase which was used in estimation of % of purity, over a period of 2 days.	The results from these studies indicated, the standard & sample solution , Mobile phase was stable at room temperature for at least 48(48h).
Robustness	A small deliberate variations in method parameters like flow rate (± 0.2 mL/min), Column oven temperature (± 5°C), and pH (± 0.2).	From the results reveal that the method is robust.

CONCLUSION

The Isocratic Rapid Resolution High Performance Liquid Chromatographic (RRHPLC) method developed for the analysis of levetiracetam in their pharmaceutical preparations is precise, accurate, and with a reasonable run time. The developed method was validated as per ICH Guidelines shows that the developed method was highly specific and robust so that it can be effec-tively applied for routine analysis in research institutions, in quality control department of pharma-ceutical industries, and in approved testing laboratories, from the above experimental data on the various method validation parameters, it is proved that this method which was designed to determine the related impurities in Levetiracetam is precise, accurate, linear, rugged, robust and range from 25% to 150% of the Specification . Hence, the method can be used for routine application.

REFERENCES

[1] Abou-Khalil B. Neuropsychiatr Dis Treat, 2008 4 (3): 507–23.
[2] BNF 59. BMA & RPSGB. 2010.
[3] Farooq MU, Bhatt A, Majid A, Gupta R, Khasnis A, Kassab MY. Am J Health Syst Pharm, 2009.66 (6): 541–61.
[4] Lynch BA, Lambeng N, Nocka K, et al.. Proc Natl Acad Sci USA., 2004 101 (26): 9861–6.
[5] Rogawski, MA. Epilepsy Research, 2006, 69 (3): 273–94.
[6] Gambardella A, Labate A, Colosimo E, Ambrosio R, Quattrone A. Neuropsychiatr Dis Treat, 2008, 4 (1): 33–8.
[7] "Clinical Epilepsy: Pediatrics". Epilepsia 2005,46 (s8): 142–67..
[8] Sai Thanuja V, Chandan R.S, gurupadayya BM, Prathyusha W, Indupriya M. Spectrophotometric determination of Levetiracetam using 2, 4-DNP in pharmaceutical dosage form. Indo American Journal of Pharmaceutical Research. 2014; 4(1): 561-565.
[9] Vermeij T.A.C, Edelbroek PM. High Performance Liquid Chromatographic and megabore Gas-Liquid Chromatographic determination of Levetiracetam (ucb L059) in human serum after solid-phase extraction. A journal of chromatography B 1994; 375(1):134-139.
[10]. Contin M, Mohamed S, Albani F, Riva R, Baruzzi A, Simple and validated HPLC-UV analysis of Levetiracetam in deproteinized plasma of patients with epilepsy. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 2008; 873(1): 129-132.
[11] Ratnaraj, Neville, Doheny, Helen C, Patsalos, Philip N. A micro method for the Determination of the New Anti-epileptic Drug Levetiracetam (ucb LO59) in Serum or Plasma by High Performance Liquid Chromatography. Journal of therapeutic.
[12] ICH Q2 (R1) Validation of analytical procedures, Text and methodology International Conference on Harmonization,Geneva. 2005; 1-17.
[13] Validation of Analytical Procedures: Q2A, Definitions and Terminology, ICH, October 1994; Q2B, Methodology, ICH, November 1996.
[14] Guideline in sterile drug products produced by aseptic processing Center for Drug Evaluation and Research Food and Drug Administration June 1987.